The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and mitigate supply chain vulnerabilities, including collaborating with the private sector to develop and implement programs to assess and incentivize resiliency in manufacturer and hospital purchasing behavior. The paper focuses on generic sterile injectable medicines used in inpatient settings, citing their importance and relative risk of supply disruptions.

Headline
The Health Sector Coordinating Council’s Cybersecurity Working Group has released a guide on third-party artificial intelligence risk and AI supply…
Headline
The White House April 2 issued a proclamation implementing additional tariffs on certain patented pharmaceutical products and ingredients. The order imposes a…
Headline
The AHA today submitted comments to the Centers for Medicare & Medicaid Services on an advanced notice of proposed rulemaking on potential options to…
Headline
The Administration for Strategic Preparedness and Response March 24 announced an investment to expand the domestic manufacturing of propofol and metoprolol.…
Headline
The Administration for Strategic Preparedness and Response announced March 5 that it will invest in the domestic production of thebaine, an ingredient…
Headline
The Supreme Court Feb. 20 ruled that the International Emergency Economic Powers Act does not authorize the imposition of global tariffs. The court held that…